Literature DB >> 26982724

Corrigendum: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.

Yu-Hwa Huang, Chen Zhu, Yasuyuki Kondo, Ana C Anderson, Amit Gandhi, Andrew Russell, Stephanie K Dougan, Britt-Sabina Petersen, Espen Melum, Thomas Pertel, Kiera L Clayton, Monika Raab, Qiang Chen, Nicole Beauchemin, Paul J Yazaki, Michal Pyzik, Mario A Ostrowski, Jonathan N Glickman, Christopher E Rudd, Hidde L Ploegh, Andre Franke, Gregory A Petsko, Vijay K Kuchroo, Richard S Blumberg.   

Abstract

Entities:  

Year:  2016        PMID： 26982724      PMCID： PMC5110397          DOI： 10.1038/nature17421

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  1 in total

1.  Diverse oligomeric states of CEACAM IgV domains.

Authors:  Daniel A Bonsor; Sebastian Günther; Robert Beadenkopf; Dorothy Beckett; Eric J Sundberg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-19       Impact factor: 11.205
  1 in total
  18 in total

1.  Glycosylation Alters Dimerization Properties of a Cell-surface Signaling Protein, Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 (CEACAM1).

Authors:  You Zhuo; Jeong-Yeh Yang; Kelley W Moremen; James H Prestegard
Journal:  J Biol Chem       Date:  2016-07-28       Impact factor: 5.157

Review 2.  CEACAM1 structure and function in immunity and its therapeutic implications.

Authors:  Walter M Kim; Yu-Hwa Huang; Amit Gandhi; Richard S Blumberg
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

Review 3.  Inhibitory receptors as targets for cancer immunotherapy.

Authors:  Meghan E Turnis; Lawrence P Andrews; Dario A A Vignali
Journal:  Eur J Immunol       Date:  2015-07       Impact factor: 5.532

Review 4.  Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.

Authors:  Guoying Zhou; Patrick P C Boor; Marco J Bruno; Dave Sprengers; Jaap Kwekkeboom
Journal:  Br J Cancer       Date:  2021-08-16       Impact factor: 9.075

5.  Knocking Out of CEACAM1 Can Reduce Oxidative Stress and Promote Cell Proliferation in the HPMVECs under Hypoxia.

Authors:  Zhixuan Li; Xiaokang He; Xueting Zhang; Junhua Zou; Hao Li; Jing Wang
Journal:  J Immunol Res       Date:  2022-06-26       Impact factor: 4.493

Review 6.  Tregs: Where We Are and What Comes Next?

Authors:  Hai Zhao; Xuelian Liao; Yan Kang
Journal:  Front Immunol       Date:  2017-11-24       Impact factor: 7.561

Review 7.  CEACAM1 as a multi-purpose target for cancer immunotherapy.

Authors:  Matthew Dankner; Scott D Gray-Owen; Yu-Hwa Huang; Richard S Blumberg; Nicole Beauchemin
Journal:  Oncoimmunology       Date:  2017-05-16       Impact factor: 8.110

Review 8.  The science is in the data.

Authors:  John R Helliwell; Brian McMahon; J Mitchell Guss; Loes M J Kroon-Batenburg
Journal:  IUCrJ       Date:  2017-10-06       Impact factor: 4.769

9.  TIGIT+ TIM-3+ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma.

Authors:  Lihua Yu; Xiaoli Liu; Xinhui Wang; Fengna Yan; Peng Wang; Yuyong Jiang; Juan Du; Zhiyun Yang
Journal:  Oncoimmunology       Date:  2021-06-28       Impact factor: 8.110

10.  CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo.

Authors:  Florian Wegwitz; Eva Lenfert; Daniela Gerstel; Lena von Ehrenstein; Julia Einhoff; Geske Schmidt; Matthew Logsdon; Johanna Brandner; Gisa Tiegs; Nicole Beauchemin; Christoph Wagener; Wolfgang Deppert; Andrea Kristina Horst
Journal:  Oncotarget       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.